Abiomed (ABMD) Tops Q2 EPS by 16c; Bumps Outlook

Abiomed (NASDAQ: ABMD) reported Q2 EPS of $0.54, $0.16 better than the analyst estimate of $0.38. Revenue for the quarter came in at $132.8 million versus the consensus estimate of $131.1 million.

The Company is again increasing the lower end of its fiscal year 2018 revenue guidance by $5 million to a new range of $565 million to $575 million, an increase in revenue of 27% to 29% from the prior year. This compares to the Company’s initial forecast of $555 million to $575 million and a 25% to 29% increase from the prior year. The Company is also increasing its fiscal year guidance for GAAP operating margin to the range of 23% to 25%, from 22% to 24%

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• LeonaBio, Inc. (LONA) Tops Q2 EPS by 32c
• Empire Petroleum posts $11.1M revenue in Q2 2026, narrows net loss